Author Affiliations: Department of Pathology, Gui de Chauliac Hospital, Montpellier, France (Dr Pernet); Department of Dermatology, University of Montpellier, St Eloi Hospital, Montpellier (Drs Pernet, Guillot, and Bessis); INSERM U1058, Montpellier (Drs Guillot and Bessis).
Ustekinumab is a human monoclonal antibody that blocks interleukin (IL)-12 and IL-23, 2 cytokines that play an important role in the pathogenesis of psoriasis.1,2 It was approved in 2009 for the treatment of adult moderate to severe chronic plaque psoriasis. We report herein the first case to our knowledge of a patient with an eczematous eruption that appeared after the administration of ustekinumab.
Pernet C, Guillot B, Bessis D. Eczematous Drug Eruption After Ustekinumab Treatment. Arch Dermatol. 2012;148(8):959-960. doi:10.1001/archdermatol.2012.586